Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 antibody-coexpressing CD19 CAR-T cells for relapsed or refractory B-cell lymphoma
ChiCTR1800018142Phase 2Recruiting
- Sponsor
- Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Start
- Sep 2018
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PD-1 antibody coexpression CD19-targeted CAR-T cells in mature B-cell lymphoma, sponsored by Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Primary endpoints: white blood cell, platelet and 10 more. Started Sep 2018; status: recruiting.
02
Drugs
PD-1 antibody coexpression CD19-targeted CAR-T cells
03
Conditions
mature B-cell lymphoma
Beyond the preview
Go deeper on ChiCTR1800018142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018142.